FDA Approves First Treatment for Patients with Cerebral Folate Transport Deficiency
The FDA approved the expanded use of Wellcovorin (leucovorin calcium) tablets to treat cerebral folate deficiency in adult and pediatric patients with a confirmed folate receptor 1 (FOLR1) gene variant.
The manufacturer of Wellcovorin, healthcare providers treating cerebral folate transport deficiency, and diagnostic laboratories focused on genetic testing for the FOLR1 variant.
This approval establishes a specific genetic requirement for the use of an existing therapy in a new indication. It suggests a focus on precision medicine approaches for rare metabolic disorders, requiring coordination between therapeutic administration and genetic diagnostic confirmation. Regulatory teams may see this as a continuation of the trend toward genotype-specific labeling for legacy compounds.
Regulatory and clinical teams should ensure that diagnostic protocols are in place to confirm the FOLR1 gene variant before initiating treatment. Labeling and promotional materials must be updated to reflect the specific genetic requirement for this expanded indication.
The U.S. Food and Drug Administration today approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1).
Open in openFDA / FDA.gov